Harry T. Robins

パートナー

New York 電話 +1.212.309.6728 Fax +1.212.309.6001

101 Park Ave.//New York, NY 10178-0060//United States

Representing Fortune 250 companies, leading private equity sponsors, and other prominent privately held clients, Harry T. Robins advises on mergers and acquisitions (M&A), and joint venture transactions before the US Federal Trade Commission (FTC), the US Department of Justice (DOJ), state Attorneys General, and international regulatory agencies. Harry heads Morgan Lewis’s transactional antitrust practice. He also has defended numerous clients in litigated antitrust cases and in government investigations and has been outside antitrust counsel for numerous Wall Street industry consortia.

Harry frequently represents clients in transactional antitrust matters when Morgan Lewis is not retained for the corporate work on the deal; destination clients of Harry’s include Apollo Management, The Intercontinental Exchange, Perrigo Company plc, Pfizer Inc., Sun Capital, Teleflex Corporation, and Zoetis Inc. among numerous others.

With respect to litigation, Harry has also successfully represented several financial institutions and life science companies in multi-defendant multidistrict antitrust and single firm monopolization cases.

Due to his knowledge and experience with the Hart-Scott-Rodino Act, Harry is often quoted in the media about issues involved in this landmark antitrust legislation. His analysis of the FTC’s proposed changes to Hart-Scott-Rodino premerger rules appeared in the publications Compliance Week and CFO.

Harry writes and speaks on antitrust matters, including a speaking engagement in a panel presentation on “Price Maintenance after Visa/MasterCard” during the Canadian Bar Association’s 2013 competition spring forum. He also delivered presentations at the American Bar Association (ABA) business law section on “Proposed Changes to the Hart-Scott-Rodino Act Rules.” He presented “Mergers—Nuts & Bolts, Distribution Practices & Competitor Collaborations in the United States: Spotting the Issues for Business Lawyers” at the ABA’s annual meeting in Toronto.

Selected Representations

On behalf of Pfizer in connection with its spinout of Upjohn and Greenstone into a new entity called Viatris to combine with Mylan N.V. (Federal Trade Commission)
On behalf of Intercontinental Exchange Inc. in the acquisition Ellie Mae
On behalf of Aurobindo in connection with its proposed acquisition of Sandoz’s generic product portfolio (Federal Trade Commission)
On behalf of Blue Cross Blue Shield Louisiana Health Services & Indemnity Co. in connection with its proposed acquisition of Vantage Holdings, Inc. (Department of Justice)
On behalf of The Intercontinental Exchange in connection with its proposed acquisition of TMC Bonds (Department of Justice)
On behalf of Securus Technologies (Platinum Equity) in connection with its proposed acquisition of Inmate Calling Solutions (Department of Justice)
On behalf of Intercontinental Exchange in connection with its acquisition of Standard & Poor’s Securities and Evaluations business from McGraw Hill Financial (Department of Justice)
On behalf of UBM in connection with the sale of PR Newswire to GTCR (Department of Justice, UK CMA)
On behalf of Pfizer Inc. in connection with its proposed $160 billion acquisition of Allergan plc (Federal Trade Commission)
On behalf of Perrigo Company plc in connection with Mylan N.V.’s unsolicited offer to acquire Perrigo Company plc (Federal Trade Commission)
On behalf of Cargill, Inc. in connection with its joint venture with ConAgra to form flour miller Ardent Mills (Department of Justice)
On behalf of Pearson plc in connection with its joint venture of Penguin and Random House (Bertelsmann) (Department of Justice)
On behalf of Pfizer Inc. in connection with its $68 billion acquisition of Wyeth (Federal Trade Commission)
On behalf of Pearson plc in connection with its acquisition of Harcourt Assessment from Reed Elsevier (Department of Justice)